Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC

NCT07309952 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Non-Small Cell Lung Cancer
Stage IIIb Non-small Cell Lung Cancer
Stage IIIC Non-Small Cell Lung Cancer

Interventions

DRUG: Sintilimab
DRUG: Paclitaxel
DRUG: Carboplatin (AUC 5)
DRUG: Pemetrexed 500 mg/m2
RADIATION: Stereotactic body radiotherapy (SBRT)
PROCEDURE: non-small cell lung cancer

Sponsor

Yang Hong